Cypress Capital Advisors, LLC Gilead Sciences, Inc. Transaction History
Cypress Capital Advisors, LLC
- $176 Billion
- Q3 2025
A detailed history of Cypress Capital Advisors, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Cypress Capital Advisors, LLC holds 1,972 shares of GILD stock, worth $244,705. This represents 0.12% of its overall portfolio holdings.
Number of Shares
1,972
Previous 1,806
9.19%
Holding current value
$244,705
Previous $200 Million
9.32%
% of portfolio
0.12%
Previous 0.13%
Shares
2 transactions
Others Institutions Holding GILD
# of Institutions
2,372Shares Held
1.01BCall Options Held
8.63MPut Options Held
7.39M-
Black Rock Inc. New York, NY121MShares$15 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA119MShares$14.8 Billion0.21% of portfolio
-
State Street Corp Boston, MA59.1MShares$7.33 Billion0.23% of portfolio
-
Capital World Investors Los Angeles, CA45.2MShares$5.61 Billion0.72% of portfolio
-
Dodge & Cox San Francisco, CA30.1MShares$3.74 Billion1.93% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $156B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...